Abciximab: A review and update for clinicians

Expert Review of Cardiovascular Therapy

Volumn 6, Issue 5, 2008, Pages 609-618

  Mazzaferri Jr , Ernest L ^a   Young, John J ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b Swedish Heart and Vascular Institute   (United States)

Author keywords

Abciximab; Acute coronary syndrome; Glycoprotein IIb IIa receptor inhibitor; GP IIb; GP IIIa; Percutaneous coronary intervention; ST elevation myocardial infarction

Indexed keywords

ABCIXIMAB; ALTEPLASE; CANGRELOR; CLOPIDOGREL; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; PLACEBO; PURINERGIC P2Y12 RECEPTOR ANTAGONIST; PURINERGIC RECEPTOR BLOCKING AGENT; RETEPLASE; STREPTOKINASE; TENECTEPLASE; THROMBIN INHIBITOR; TICAGRELOR; TIROFIBAN; UNCLASSIFIED DRUG; ANTITHROMBOCYTIC AGENT; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY;

ACUTE CORONARY SYNDROME; BLEEDING; BLOOD CLOT LYSIS; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; DRUG CHOICE; DRUG COST; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG SAFETY; EVIDENCE BASED MEDICINE; FIBRINOLYTIC THERAPY; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK POPULATION; HUMAN; LOW DRUG DOSE; MONOTHERAPY; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; PSEUDOTHROMBOCYTOPENIA; REVIEW; SINGLE DRUG DOSE; ST SEGMENT ELEVATION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBUS; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS; ANGIOCARDIOGRAPHY; DOSE RESPONSE; DRUG ADMINISTRATION; ELECTROCARDIOGRAPHY; FEMALE; HOSPITALIZATION; MALE; METHODOLOGY; MORTALITY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; CORONARY ANGIOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 47149113331     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.6.5.609     Document Type: Review

References (68)

1. Dotter CT, Judkins MP. Transluminal treatment of arteriosclerotic obstruction: description of a new technique and a preliminary report of its application. Circulation 30, 654 (1964).
2. Gruentzig A, Kumpe DA. Technique of percutaneous transluminal angioplasty with the Gruentzig balloon catheter. AJR Am. J. Roentgenol. 132, 547 (1979).
3. Topol EJ. Bonan R. Jewitt D et al. Use of a direct antithrombin, Hirulog, in place of heparin during coronary angioplasty. Circulation 87(5), 1622-1629 (1993).
4. The Benestent Study Group. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N. Engl. J. Med. (8)331, 489-495 (1994).
5. The Stent Restenosis Study Investigators. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N. Engl. J. Med. (8)331, 496-501 (1994).
6. The Gianturco-Roubin Intracoronary Stent Investigator Group. Major clinical events after coronary stenting, the multicenter registry of acute and elective gianturco-roubin stent placement. Circulation 89, 1126-1137 (1994).
7. Kong DF, Califf RM, Miller DP et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 98, 2829-2835 (1998).
8. Coller BS. 1985, a new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J. Clin. Invest. 76, 101-108 (1985).
9. Plow EF, Ginsberg MH. Cellular adhesion: GP IIb/IIIa. as a prototypic adhesion receptor. Prog. Hemost. Thromb. 9, 117 (1989).
10. ACC/AHA/SCAI Writing Committee. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline for Percutancous Intervention. J. Am. Coll. Cardiol. 51(2), 172-209 (2008).
11. ACC/AHA Writing Committee. ACC/AHA Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction. J. Am. Coll. Cardiol. 44, 671-719 (2004).
12. Montalescot G et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N. Engl. J. Med. 344(25), 1895-1903 (2001).
13. Antoniucci D, Rodriguez A, Hempel A et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J. Am. Coll. Cardiol. 42(11), 1879-1885 (2003).
14. The ReoPro Readministration Registry Investigators. Abciximab readministration: results of the ReoPro Readministration Registry. Circulation 104, 870-875 (2001).
15. Simonton CA, Mark DB, Hinohara T et al. Late restenosis after emergent coronary angioplasty for acute myocardial infarction: comparison with elective coronary angioplasty. J. Am. Coll. Cardiol. 11, 698-705 (1988).
16. Neumann FJ, Kastrati A, Schmitt C et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J. Am. Coll. Cardiol. 35(4), 915-921 (2000).
17. Karvouni E, Katritsis DG, Ioannidis JP et al. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous interventions. J. Am. Coll. Cardiol. 41, 26-32 (701) (2003).
18. Bakhai A, Stone G, Grines C. Cost-effectiveness of coronary stenting and abciximab for patients with acute myocardial infarction. Circulation 108, 2857-2863 (2003).
19. McCollam P, Foster D, Reismeyer J. Cost and effectiveness of glycoprotein IIb/IIIa receptor inhibitors in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Am. J. Health-Syst. Pharm. 60, (2003).
20. Coller BS, Peerschke EI, Scudder LE et al. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produced a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J. Clin. Invest. 72, 325-338 (1983).
21. Becker RC. Clinical trials of platelet glycoprotein IIb/IIIa receptor inhibitors in coronary heart disease: intravenous agents. Up ToDate (2006).
22. Mager DE, Mascelli MA, Kleiman NS et al. Simultaneous modeling of abciximab plasma concentrations and ex vivo pharmacodynamics in patients undergoing coronary angioplasty. J. Pharmacol. Exp. Ther. 307, 969-976 (2003).
23. ReoPro® (abciximab), Package insert. Centocor BV,Leiden, The Netherlands (1997).
24. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N. Engl. J. Med. 330, 956-961 (1994).
25. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 349, 1429-1435 (1997).
26. The EPILOG Investigators. Platelet IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N. Engl. J. Med. 336, 1689.
27. Bougie DW, Wilker PR, Wuitschick ED et al. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GP IIb/IIIa. Blood 100(6), 2071-2076 (2002).
28. Dasgupta H, Blankenship JC, Wood GC et al. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis. Am. Heart J. 140(2), 206-211 (2000).
29. Merlini PA, Rossi M, Menozzi A et al. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Circulation 109(18), 2203-2206 (2004).
30. Berkowitz SD, Sane DC, Sigmon KN et al.; Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. J. Am. Coll. Cardiol. 32(2), 311-319 (1998).
31. Curtis BR, Divgi A, Garritty M et al. Delayed thrombocytopenia after treatment with abciximab: a distinct clinical entity associated with the immune response to the drug. J. Thromb. Haemost.2, 985-992 (2004).
32. Reddy MS, Carmody TJ, Kereiakes DJ. Severe delayed thrombocytopenia associated with abciximab (ReoPro) therapy. Catheter. Cardiovasc. Interv. 52, 486-488 (2001).
33. Nurden P, Clofent-Sanchez G, Jais C et al. Delayed immunologic thrombocytopenia induced by abciximab. Thromb. Haemost. 92, 820-828 (2004).
34. Kaluski E, Leitman M, Khiger I et al. Delayed thrombocytopenia following abciximab therapy. Int. J. Cardiovasc. Interv. 4, 151-155 (2001).
35. Huxtable LM, Tafteshi MJ, Rakkar AN. Frequency and management of thrombocytopenia with the glycoprotein IIb/IIIa receptor antagonists. Am. J. Cardiol. 97(3), 426-429 (2006).
36. Sane DC, Damaraju LV, Topol EJ et al. Occurrence of clinical significance of pseudothrombocytopenia during abciximab therapy. J. Am. Coll. Cardiol. 36(1), 75-83 (2000).
37. Berkowitz SD, Harrington RA,, Rund MM et al. Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. Circulation 95(4), 809-813 (1997).
38. Llevadot J, Coulter SA, Giugliano R.P. A practical approach to the diagnosis and management of thrombocytopenia associated with glycoprotein IIb/IIIa receptor inhibitors. J. Thromb. Thrombolysis 9(2), 175-180 (2000).
39. Bishara AI, Hagmeyer KO. Acute profound thrombocytopenia following abciximab therapy. the annals of pharmacotherapy. Ann. Pharmacother. 34, 924-930 (2000).
40. Keriakes DJ, Essell JH, Abbottsmith CW et al. Abciximab-associated profound thrombocytopenia: therapy with immunoglobulin and platelet transfusion. Am. J. Cardiol. 78, 1161-1163 (1996).
41. Brener SJ, Barr LA, Burchenal JEB et al.; the RAPPORT Investigators. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation 98, 734-741 (1998).
42. Rothobaum D, Linnemeier T, Landin R et al. Emergency percutaneous transluminal coronary angioplasty in acute myocardial infarction: a 3-year experience. J. Am. Coll. Cardiol. 10, 264-272 (1987).
43. Ellis S, O'Neill W, Bates E et al. Implications for patient triage from survival and left ventricular functional recovery analyses in 500 patients treated with coronary angioplasty for acute myocardial infarction. J. Am. Coll. Cardiol. 13, 1251-1259 (1989).
44. Kahn J, Rutherford B, McConahay D et al. Results of primary angioplasty for acute myocardial infarction in patients with multivessel coronary artery disease. J. Am. Coll. Candiol. 16, 1089-1096 (1990).
45. Grines CL, Browne KF, Marco J et al.; Primary Angioplasty in Myocardial Infaraion Study Group. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N. Engl. J. Med. 328, 685-691 (1993).
46. Gibbons RJ, Holmes DR, Reeder GS et al. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. N. Engl. J. Med. 328, 685-691 (1993).
47. de Boer MJ, Hoorrtje JC, Ottervanger JP et al. Immediate coronary angioplasty versus intravenous streptokinase in acute myocardial infarction: left ventricular ejection fraction, hospital mortality and reinfarction. J. Am. Coll. Cardiol. 23, 1004-1008 (1994).
48. Stone GW, Grines CL, Cox DA et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N. Engl. J. Med. 346(13), 957-966 (2002).
49. De Luca G, Suryapranata H, Stone GW et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 293(14), 1759-1765 (2005).
50. ACC/AHA/SCAI Writing Committee. ACC/AHA/SCAI guideline update for percutaneous coronary intervention. Circulation 113(1), 156-175 (2005).
51. Gibson CM, Cannon CP, Murphy SA et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 101, 125-130 (2000).
52. Antman EM, Giugliano RP, Gibson CM et al. Abciximab ficilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. Circulation 99, 2720-2732 (1999).
53. SPEED Investigators. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. Circulation 101(24), 2788-2794 (2000).
54. Topol EJ. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomized trial. Lancet 357(9272), 1905-1914 (2001).
55. ASSENT-3 Investigators. Efficacy and Safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomized trial in acute myocardial infarction. Lancet 358(9282), 605-613 (2001).
56. Ellis S. European Society of Cardiology Congress. Vienna, Austria 3 September 2007.
57. Antman EM, Hand M, Armstrong PW et al. 2007 Focused update of the ACC/AHA 2004 guidelines for the management of st-elevation myocardial infarction. J. Am. Coll. Cardiol. 51, 210-247 (2008).
58. Topol EJ, Califf RM, Weisman HF et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for the reduction of clinical restenosis: results at six months. Lancet 343(8902), 881-886 (1994).
59. Topol EJ, Ferguson JJ, Weisman HF et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin 3 blockade with percutaneous coronary intervention, JAMA 278(6), 479-484 (1997).
60. Van den Brand M, Laarman GJ, Steg PG et al. Assessment of coronary angiograms prior to and after treatment with abciximab, and the outcome of angioplasty in refractory unstable angina patients. Angiographic results from the CAPTURE trial. Eur. Heart J. 20(21), 1572-1578 (1999).
61. Simoons ML. Effect of glycoprotein IIb/IIIa receptor blockade on outcome in patients with acute coronary syndromes without early coronary revascularization: the GUSTO IV-ACS randomized trial. Lancet 357(9272), 1915-1924 (2001).
62. ACC/AHA UA/NSTEMI 2007. Guideline Revision. J. Am. Coll. Cardiol. 50, 1-157 (2007).
63. Kastrati A, Mehilli J, Neumann FJ et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment. JAMA 295, 1531-1538 (2006).
64. The EPISTENT Investigators. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 352(9122), 87-92 (1998).
65. The ERASER Investigators. Acute platelet inhibition with abciximab does not reduce in-stent restenosis. Circulation 100(8), 799-806 (1999).
66. Kastrati A, Mehilli J, Schuhlen H et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N. Engl. J. Med. 350(3), 232-238 (2004).
67. Mehilli J, Kastrati A, Schuhlen H et al. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous elective coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 110(24), 3627-3635 (2004).
68. Cattaneo M. Platelet P2 receptors: old and new targets for antithrombotic drugs. Expert Rev. Cardiovasc. Ther. 5(1), 45-45 (2007).